This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Discriminant Function Analysis of Fluorodopa F 18 Positron Emission Tomography Data

Guy V. Sawle, DM; E. Diane Playford, MRCP; David J. Burn, MRCP; Vincent J. Cunningham, PhD; David J. Brooks, MD

Arch Neurol. 1994;51(3):237-243.

Abstract
Objective
To explore the relationship between normal and parkinsonian fluorodopa F 18 (¹⁸F-6-L-fluorodopa [¹⁸F-dopal]) uptake data to identify clinically normal subjects who may have preclinical Parkinson's disease.

Design
A statistical comparison of striatal fluorodopa F 18 positron emission tomography scan data from patients with Parkinson's disease and normal controls.

Setting
Positron emission tomography unit within a postgraduate teaching hospital.

Main Outcome Measures
Discriminant function analysis used to compare the pattern of striatal (left and right caudate and putamen) fluorodopa F 18 uptake in normal subjects and patients with Parkinson's disease. Results: The discriminant score that best separates patients with Parkinson's disease from normal controls is a function of the lowest putamen influx constant minus a function of the caudate influx constant values. Borderline low normal subjects have slightly low fluorodopa F 18 uptake throughout the striatum, whereas patients with early Parkinson's disease have low fluorodopa F 18 uptake in one putamen with preserved uptake in the caudate (for normal subjects, subtracting the caudate influx constants from a function of the lowest putamen value lowers the discriminant score, although it remains positive; for patients, subtracting a larger caudate value from a function of the putamen uptake value leads to a negative score). One control subject had a borderline low discriminant score, compatible with focal nigral pathological changes as expected in preclinical Parkinson's disease. A repeated scan taken 3 years later showed a marked reduction in fluorodopa F 18 uptake, suggesting progressive nigral dysfunction.

Conclusion
Normal and parkinsonian fluorodopa F 18 uptake data differ both in the overall level of tracer uptake and in its spatial distribution. Subjects whose overall striatal fluorodopa F 18 uptake falls at the borderline of normal and parkinsonian values are likely to be normal if they have uniformly low uptake, but may have early or preclinical Parkinson's disease if uptake into putamen is very much lower than uptake into caudate.

Author Affiliations
From the MRC Cyclotron Unit (Drs Sawle, Playford, Burn, and Brooks), Clinical Sciences Section, and the MRC Cyclotron Unit Biology Section (Dr Cunningham), Hammersmith Hospital, London, England, and the University Department of Clinical Neurology (Drs Sawle and Brooks), Institute of Neurology, National Hospitals for Neurology and Neurosurgery, London, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Can we image premotor Parkinson disease?
Marek and Jennings
Neurology 2009;72:S21-S26.
ABSTRACT | FULL TEXT  

Biomarkers and Parkinson's disease
Michell et al.
Brain 2004;127:1693-1705.
ABSTRACT | FULL TEXT  

Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa
Marek et al.
Neurology 2003;61:S43-48.
FULL TEXT  

Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
Parkinson Study Group
JAMA 2002;287:1653-1661.
ABSTRACT | FULL TEXT  

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism
Neurology 2000;55:1540-1547.
ABSTRACT | FULL TEXT  

Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging
Hutchinson and Raff
Am. J. Neuroradiol. 2000;21:697-701.
ABSTRACT | FULL TEXT  

Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra
Hutchinson and Raff
J. Neurol. Neurosurg. Psychiatry 1999;67:815-818.
ABSTRACT | FULL TEXT  

Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging
Marek
Neuroscientist 1999;5:333-340.
ABSTRACT  

Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
Bennett et al.
NEJM 1996;334:71-76.
ABSTRACT | FULL TEXT